DailyWealth Investment Newsletter  

About DailyWealth Premium Content DailyWealth Archive
DailyWealth Investment Newsletter DailyWealth Contributors DailyWealth Resources DailyWealth Market Window
 
DailyWealth Print Edition Print Edition | Sponsored Link:
True Wealth Login

What a Tiny Hungarian Company Taught Me About Dividends
By Tom Dyson
July 28, 2008

I started my job at Citigroup in London in April 2000... a month after the Nasdaq bubble burst and the beginning of the worst bear market in stocks since 1973-1974.

As a junior accountant, my first job was dividend control. I made sure hundreds of Citigroup stock traders received the correct dividend payments on the positions they held. And when investors didn't get what they were owed, I contacted Citigroup's clearing department and made the claim.

I remember one trader, Nick Rubeiro. He ran an emerging-market high-yield strategy from a desk in New York. He had the most obscure companies in his portfolio, and they always tripped up the computer systems.

"Mol Magyar pays tomorrow," he'd say about the Hungarian oil company. "I'm holding 100 million shares."

Then I'd find out he actually owned 125 million shares. That's a $7.5 million dividend.

I saw dozens of traders come and go on the trading floor that summer. The market was an absolute bloodbath. But every week, I'd get the same call from New York Nick chasing his missed distributions.

The Three Best
Gold Investments Right Now

Simply sign up to receive, DailyWealth, and we'll immediately e-mail you this latest research report...
Absolutely FREE:

Nick's quarterly dividend payments became something of a symbol for me that summer... like a pillar of strength amidst all the carnage of the stock market. They pulled me off dividend control later that year and sent me to fixed income. But I never forgot about Nick's dividends...

Economists define a bear market as a 20% drop in the S&P index. The S&P is the index of the 500 largest companies in America. So it's the best way to determine how American stocks are behaving. In 2008, the S&P entered bear-market territory for the first time since 2002. As I write, the S&P is down 20% since October 2007... but it was down more than 25% two weeks ago.

This is only the fifth time in last 100 years we've seen a 25% or greater decline in the S&P 500.

But while everyone else panics, subscribers to my 12% Letter are keeping calm. In the middle of one of the five worst bear markets in 100 years, the stocks in The 12% Letter portfolio continue to pile on the dividends...

High-dividend stocks are defensive by nature. The dividend acts like an anchor and prevents a stock price from falling too far. As stock prices fall, yields rise... enticing investors to buy the stock. This is only if the company maintains or raises its dividend. These are the companies we buy in The 12% Letter. In weak companies, a high-dividend yield is a warning sign. I especially like companies with long track records of rising dividends through many economic cycles...

Related Articles

There's Never Been a Better Time to Be an Income Investor

The Two Best Stocks to Own in a Recession

For example, we've made 53% on McDonald's and 23% on Wal-Mart as consumers have tended toward low prices. Wal-Mart has 30 years of unbroken dividend growth. McDonald's has 29 years.

We piled into defensive assets like timberland, Canadian energy, coal, pipelines, and rural telecom... and made gains of 15%, 71%, 80%, 9%, and 6%.

The current positions in my portfolio are up 9% on average... and paying 10% annual dividends... in a bear market.

As I wrote in Wednesday's DailyWealth, over 400 stocks are trading in U.S. markets with yields above 7%. Now is a great time to be buying high-yield stocks. They'll shelter your money from the bear market... while generating double-digit returns.

Good investing,

Tom

Editor's note: Tom Dyson is a regular contributor to DailyWealth, a free investment newsletter focused on the world's best contrarian opportunities. We write with a simple belief in mind: You don't have to take big risks to make big money with your investments.

Sign up today to read more investment ideas from Tom Dyson.

Email a Friend

Delicious
Reddit

Digg

RSS

NEW HIGHS OF NOTE LAST WEEK

The biotech boom has begun!
Micromet (MITI)... biotech
Genentech (DNA)... biotech
Myriad Genetics (MYGN)... biotech
Nabi Pharmaceuticals (NABI)... biotech
Emergent BioSolutions (EBS)... biotech
Alexion Pharmaceuticals (ALXN)... biotech
Biotech HOLDRs (BBH)... biotech ETF
S&P Biotech (XBI)... biotech ETF
CryoLife (CRY)... biotech & medical
Novartis (NVS)... blue-chip drugmaker
Steris Corp (STE)... medical equipment
Valeant Pharma (VRX)... drugmaker
J.B. Hunt (JBHT)... trucking
Old Dominion (ODFL)... trucking
Arkansas Best (ABFS)... trucking
Heartland Express (HTLD)... trucking

Equity Residential (EQR)... apartment REIT

NEW LOWS OF NOTE LAST WEEK

Coca-Cola (KO)... soda
Merck (MRK)... drugs
Sturm, Ruger (RGR)... guns
FortuNet (FNET)... gambling
New Frontier Media (NOOF)... porn
Banro (BAA)... African gold
Virgin Media (VMED)... British media
51job (JOBS)... Chinese job search
Hellenic Telecom (OTE)... Greek telecom
America Movil (AMX)... Latin American telecom
Templeton Russia Fund (TRF)... Russian stocks
Chipotle Mexican Grill (CMG)... Mexican food

Mortgage rates shot up [last] week, with 30-year mortgages climbing to the highest level in nearly a year, reflecting concerns in financial markets about the troubles at corporate giants Fannie Mae and Freddie Mac.

Freddie Mac reported Thursday that its nationwide survey showed rates on 30-year mortgages surged to an average of 6.63% this week, up sharply from 6.26% last week. That was the highest level for 30-year mortgages since they averaged 6.68% the week of Aug. 1.

USA Today

In 1990, Swiss drug company Roche acquired a majority stake in Genentech. Roche became Genentech's exclusive European distributor.

Today, Genentech's drugs represent 30% of Roche's pharmaceutical sales. And as Genentech's largest shareholder, Roche has multiplied its money about 40 times in two decades.

While I believe the bid is a bad move for Roche – and not a great proposal for Genentech shareholders – this mega-deal is actually good for the entire biotech industry... and its investors.

With Genentech gone, the top of the biotech food chain is empty. Many investors will be searching for new spots to park their biotech cash. And sector valuations are on the rise. Both major biotech indexes – the Nasdaq Biotech Index and AMEX Biotech Index – are up more than 7% in just a few weeks.
– Rob Fannon,
The Growth Stock Wire
Advertisement

After 20 Years of Ignoring This Investment, It's Finally Time to Buy
July 26, 2008

What Really Makes Gold Go Up? It's Happening Now...
July 25, 2008

Why the Mania Phase in Gold May Be Upon Us
July 24, 2008

There's Never Been a Better Time to Be an Income Investor
July 23, 2008

Biotech's Next Big Bull Market Starts Now
July 22, 2008

Home | About DailyWealth | Premium Content | DailyWealth Archive | Contributors
DailyWealth Resources | Research Reports | Privacy Policy

Customer Service: 1-888-261-2693 – Copyright 2008 Stansberry & Associates Investment Research. All Rights Reserved. Protected by copyright laws of the United States and international treaties. This e-letter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Stansberry & Associates Investment Research, LLC. 1217 Saint Paul Street, Baltimore MD 21202